

Practitioner's Docket No. 2003DE418

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Uwe Falk et al.

Application No.: 10/554,190

Group No.: 1792

Filed: October 21, 2005

Examiner: Cameron, E.C.

For: Use Of Polysilazane For The Production Of Hydrophobically And
Oleophobic Modified Surfaces

INFORMATION DISCLOSURE STATEMENT

**Commissioner for Patent
P.O. Box 1450
Alexandria, VA 22313-1450**

Dear Sir:


In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. ☒ Enclosures accompanying this Information Disclosure Statement are:
 - 1a. ☒ Form PTO/SB/08A.
 - 1b. ☐ Copies of Information Disclosure Statement citations.
 - 1c. ☐ PCT Search Report
 - 1d. ☒ Citation of Co-pending U.S. Applications.
2. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.

4. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. ☒ This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.
7. ☐ The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached Form PTO/SB/08A are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached Form PTO/SB/08A.
8. ☒ In addition to the documents cited, the Office's attention is directed to the following co-pending U.S. Application Serial Number(s):
- a. US Serial No. 10/585,392, filed 07/06/2006, by Dierdorf, et al., now US 2007/0116968 A1,
 - b. US Serial No. 10/591,623, filed 11/29/2006, by Brand, et al., now US 2007/0190308 A1,
 - c. US Serial No. 10/591,573, filed 09/01/2006, by Brand, et al., now US 2007/0196672 A1,
 - d. US Serial No. 11/791,550, filed 05/23/2007, by Brand, et al., now US 2008/0107894 A1,

e. ,
f. ,
g. ,
h. ,
i. ,
j. ,
k. ,
l. .

Respectfully submitted,



Tod A. Waldrop, Ph.D.
Registration No. 56,260

CUSTOMER NO. 25,255

Clariant Corporation
Industrial Property Department
4000 Monroe Road
Charlotte, North Carolina 28205
Telephone: 704/331-7732
Facsimile: 704/331-7707